

# **The Gene Expression Level of Transforming Growth Factor-beta (TGF- beta) and Significance of Survivin in Hepatocellular Carcinoma**

**Submitted by**  
**Ahmed Fathi Soliman Mohamed**  
(M.Sc. in Biochemistry, 2007)

**For the Fulfillment of the Degree of Doctor of Philosophy in  
Biochemistry**

**Under Supervision of**

**Prof. Dr. Abdel Halim A. Mostafa**

Professor of Biochemistry  
Faculty of Science  
Ain Shams University

**Prof. Dr. Sanaa M. Kamal**

Professor of Gastroenterology &  
Hepatology  
Faculty of Medicine  
Ain Shams University

**Prof. Dr. Amany A. Ibrahim**

Professor of Gastroenterology &  
Hepatology  
Faculty of Medicine  
Ain Shams University

**Dr. Mahmoud M. Said**

Lecturer of Biochemistry  
Faculty of Science  
Ain Shams University

Biochemistry Department  
Faculty of Science  
Ain Shams University  
2013

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا

إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ

الْحَكِيمُ﴾

صدق الله العظيم

البقرة - الآية 32

**Ain Shams University**  
**Faculty of Science**

**Name** : Ahmed Fathi Soliman Mohamed  
**Scientific Degree** : M.Sc. in Biochemistry  
**Department** : Biochemistry  
**Faculty** : Science  
**University** : Ain Shams  
**Graduation Year** : 2002

*I declare that this thesis has been composed by myself and the work herein has not been submitted for a degree at this or any other university.*

*Ahmed Fathi Soliman*

*I dedicate this work to my mother's soul, my father and my family. I have to thank them for supporting me with kindness and patience.*

*Ahmed Fathi Soliman*

## ***Acknowledgment***

*First and foremost thanks to “Allah”, the most Merciful for guiding me through and giving me the strength to complete this work the way it is.*

*I would like to express my deep thanks and supreme gratitude to **Professor Dr. Abdel-Halim A. Mostafa**, Professor of Biochemistry, Faculty of Science, Ain Shams University not only for giving me the chance to work under his supervision, but also for the great scientific help and continuous guidance which lead to emergence of this work in its current form.*

*I do feel greatly indebted to **Professor Dr. Sanaa M. Kamal**, Professor of Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University for suggesting the point, designing the work, her close supervision and valuable instructions throughout this thesis.*

*I would like to express my thanks to **Professor Dr. Amany A. Ibrahim**, Professor of Gastroenterology and*

*Hepatology, Faculty of Medicine, Ain Shams University for her support throughout this work.*

*I am also deeply grateful to **Dr. Mahmoud M. Said**, Lecturer of Biochemistry, Faculty of Science, Ain Shams University for his skillful help, excellent finishing of the work and discussion during all stages of the research and preparation of the thesis.*

*Last, my deep appreciation to Chairman, Professors and Colleagues of the Biochemistry Department, Faculty of Science, Ain Shams University, Professors and Physicians of Gastroenterology and Hepatology, Ain Shams Hospitals, for their support and encouragement.*

**Ahmed F. Soliman**

# **The Gene Expression Level of Transforming Growth Factor-beta (TGF-beta) and Significance of Survivin in Hepatocellular Carcinoma**

Ahmed F. Soliman

Faculty of Science, Ain Shams University

## ***Abstract***

**Background and objective:** Transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) plays an important role in the regulation of cell growth and differentiation, angiogenesis, extracellular matrix formation, immunosuppression and cancer development. Survivin was shown to inhibit apoptosis and accelerate cancer cell proliferation as well. In this study, investigation included the levels of circulating TGF- $\beta$ 1 and hepatic TGF- $\beta$ 1 mRNA expression, and their diagnostic value for hepatocellular carcinoma (HCC). Also expression of survivin protein was investigated which may be of a diagnostic significance and therapeutic relevance in HCC.

**Patients and methods:** A total of 50 individuals were enrolled, which included 24 patients with primary HCC, 21 with chronic hepatitis C virus (HCV) infection, as well as 5 healthy subjects.

TGF- $\beta$ 1 gene expression level of tumors and of non-cancerous livers was analyzed by real-time reverse transcriptase polymerase chain reaction (RT-PCR), while serum TGF- $\beta$ 1 and AFP were assessed by enzyme linked immune-sorbent assay (ELISA). Also the expression of survivin protein was detected by immunohistochemistry and the percentage of apoptotic cells (apoptotic index; AI) was evaluated with TUNEL assay.

**Results:** The patients with HCC had significantly higher hepatic TGF- $\beta$ 1 gene expression levels ( $87.55 \pm 15.22$ ; mean  $\pm$  SE) than HCV patients ( $22.7 \pm 4.21$ ) ( $p < 0.001$ ), also serum TGF- $\beta$ 1 was significantly increased in



HCC patients ( $16.93 \pm 0.90$  ng/ml) as compared to HCV patients ( $13.67 \pm 0.81$  ng/ml) ( $p < 0.05$ ). Survivin expression and TUNEL labeling index (LI) for apoptotic cells were significantly higher in HCC than in HCV livers ( $p < 0.05$  and  $p < 0.001$ , respectively).

The sensitivity, specificity, positive and negative predictive values of hepatic TGF- $\beta$ 1 gene expression was 91.7, 76.2, 81.5, and 88.9%, respectively, while the values for serum TGF- $\beta$ 1 were 75, 61.9, 69.23, and 68.42%, respectively. Combining hepatic TGF- $\beta$ 1 gene expression and either serum TGF- $\beta$ 1 or serum AFP raised the sensitivity to 95.8%. Also, combining serum TGF- $\beta$ 1 and serum AFP raised the specificity to 95.2%.

In HCV patients, a positive correlation between serum AFP level and hepatic survivin protein expression was recorded. Also, hepatic TGF- $\beta$ 1 gene expression level was correlated positively with serum TGF- $\beta$ 1 level. In HCC patients, survivin protein expression was correlated negatively with TUNEL LI. On the other hand, serum AFP level was correlated positively with HCC grade and stage.

**Conclusion:** The over-expression of TGF- $\beta$ 1 gene and its downstream protein level could lead to enhanced tumor cell proliferation. Also TGF- $\beta$ 1 serum concentration may help early diagnosis of HCC. Concerning survivin, it may be a useful diagnostic marker of cancer and a potential target for cancer treatment.

## *Contents*

	<i>Page</i>
List of tables.....	i
List of figures .....	iii
List of abbreviations .....	Vi
Introduction .....	Xi
Aim of the work .....	Xiii

### **I. Review of Literature**

• Hepatocellular carcinoma .....	1
• Epidemiology .....	2
• Risk factors .....	5
A. Viral hepatitis .....	5
➤ Hepatitis B virus (HBV) .....	5
➤ Hepatitis C virus (HCV) .....	10
B. Diabetes mellitus .....	14
C. Aflatoxin B1 .....	16
D. Pesticides .....	17
• Diagnosis of HCC .....	18
• HCC specific biomarkers .....	18
➤ Alpha feto-protein .....	18
➤ Des-γ-Carboxyprothrombin .....	22
➤ α-L-Fucosidase .....	22
➤ γ-Glutamyl transferase .....	23

➤ Glypican-3 .....	23
➤ Squamous cell carcinoma antigen .....	24
• Radiological techniques for HCC diagnosis .....	25
• Transforming growth factor beta .....	27
• Activation of transforming growth factor- $\beta$ .....	29
• Structure and activation of TGF- $\beta$ receptors (T $\beta$ Rs) .....	31
• Intracellular signaling of TGF- $\beta$ .....	34
• TGF- $\beta$ induced growth arrest .....	36
• TGF- $\beta$ induced apoptosis .....	38
• TGF- $\beta$ and cancer .....	41
➤ Alterations of TGF- $\beta$ signalling pathways contribute to tumor risk .....	41
➤ TGF- $\beta$ 1 as a pro-angiogenic factor .....	43
➤ Role of TGF- $\beta$ in tumor-mediated immunosuppression .....	44
• Survivin .....	45
• Molecular organization and structure of survivin .....	46
• Role of survivin in cell division .....	49
• Role of survivin in apoptosis .....	51
• Role of survivin in cancer .....	53

## II. Subjects and Methods

II.1. Subjects .....	56
II.1.1. Sample collection and separation .....	58
II.2. Methods.....	59
II.2.1. Determination of Serum Alpha-Feto Protein by Enzyme Linked Immunosorbent Assay .....	59
II.2.2. Determination of Serum Transforming Growth Factor- $\beta$ 1 by Enzyme Linked Immunosorbent Assay .....	62
II.2.3. Determination of Transforming Growth Factor- $\beta$ 1	

Relative Gene Expression Level by Real Time Polymerase Chain Reaction .....	67
A- RNA Extraction .....	68
B- Reverse Transcription of RNA .....	74
C- Quantitative real time polymerase chain reaction (qRt-PCR) for TGF- $\beta$ 1 .....	77
II.2.4. Determination of Survivin Protein Expression by Immunohistochemistry .....	86
II.2.5. Terminal Deoxyuridine Triphosphate Nick-End Labeling (TUNEL) for the Detection of Apoptotic Cells .....	91
• Statistical analysis .....	96
<b>III. Results</b> .....	97
<b>IV. Discussion</b> .....	121
<b>V. Summary</b> .....	141
<b>References</b> .....	146
<b>Appendix</b> .....	175
<b>Arabic Summary</b>	
<b>Arabic Abstract</b>	

## *List of Tables*

<i>Table No.</i>	<i>Subject</i>	<i>Page</i>
<b>1.1</b>	Diagnostic value of AFP as a HCC biomarker	<b>20</b>
<b>3.1</b>	Clinicopathological data for HCC patients	<b>97</b>
<b>3.2</b>	Individual data of serum $\alpha$ -feto protein (AFP) and transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) levels, hepatic TGF- $\beta$ 1 relative gene expression, surviving expression as well as TUNEL labeling index in HCV patients	<b>98</b>
<b>3.3</b>	Individual data of serum $\alpha$ -feto protein (AFP) and transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) levels, hepatic TGF- $\beta$ 1 relative gene expression, survivin expression as well as TUNEL labeling index in HCC patients	<b>99</b>
<b>3.4</b>	Serum $\alpha$ -feto protein (AFP) and transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) levels, hepatic TGF- $\beta$ 1 relative gene expression and TUNEL labeling index in HCV and HCC patients	<b>100</b>
<b>3.5</b>	Survivin expression in liver sections of HCV and HCC patients	<b>105</b>
<b>3.6</b>	Localization of intracellular survivin expression in HCV and HCC patients	<b>106</b>
<b>3.7</b>	Diagnostic value of markers to distinguish between HCV and HCC	<b>116</b>
<b>3.8</b>	Crosstabulation showing the reliability of markers in differentiating between HCV and HCC	<b>116</b>
<b>3.9</b>	Combinational ROC analysis of hepatic TGF- $\beta$ 1 relative gene expression, serum TGF- $\beta$ 1 and serum AFP	<b>118</b>
<b>3.10</b>	Crosstabulation showing the reliability of calculated markers in differentiating between HCV and HCC	<b>118</b>

### *List of Tables (Cont.)*

<i>Table No.</i>	<i>Subject</i>	<i>Page</i>
<b>3.11</b>	Relationship of survivin expression with hepatic TGF- $\beta$ 1 relative gene expression, serum TGF- $\beta$ 1 and serum AFP in HCC patients	<b>120</b>
<b>I</b>	Individual data of gender, age, complete blood picture and plasma prothrombin time (PT) in HCV patients	<b>175</b>
<b>II</b>	Individual data of gender, age, complete blood picture and plasma prothrombin time (PT) in HCC patients	<b>176</b>
<b>III</b>	Complete blood picture and plasma prothrombin time (PT) in HCV and HCC patients	<b>177</b>
<b>IV</b>	Individual data of hepatic marker parameters level and vireamia load in HCV patients	<b>178</b>
<b>V</b>	Individual data of hepatic marker parameters level, vireamia load and clinicopathological data in HCC patients	<b>179</b>
<b>VI</b>	Levels of hepatic marker parameters and vireamia load in HCV and HCC patients	<b>180</b>
<b>VII</b>	Individual data of gender, age and complete blood picture in controls	<b>181</b>
<b>VIII</b>	Individual data of hepatic marker parameters level and vireamia load in controls	<b>181</b>
<b>IX</b>	Individual data of serum $\alpha$ -feto protein (AFP) and transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) levels, hepatic TGF- $\beta$ 1 relative gene expression and TUNEL labeling index in controls	<b>181</b>

## *List of Figures*

<i>Fig. No</i>	<i>Title</i>	<i>Page</i>
<b>1.1</b>	Mechanism of hepatitis B virus-associated hepatocarcinogenesis	<b>8</b>
<b>1.2</b>	Schematic organisation of the hepatitis B virus genome	<b>9</b>
<b>1.3</b>	Evolution from HCV infection to HCC	<b>11</b>
<b>1.4</b>	Hepatitis C virus (HCV) genome including the long open reading frame encoding structural and non-structural genes, and 5' and 3' non coding regions	<b>12</b>
<b>1.5</b>	Possible multiple roles of TGF- $\beta$ in tumor pathogenesis	<b>28</b>
<b>1.6</b>	Latent TGF- $\beta$ complexes	<b>30</b>
<b>1.7</b>	Activation of latent TGF- $\beta$	<b>31</b>
<b>1.8</b>	Activation of T $\beta$ Rs	<b>33</b>
<b>1.9</b>	TGF- $\beta$ signal transduction	<b>33</b>
<b>1.10</b>	TGF- $\beta$ signalling pathways	<b>35</b>
<b>1.11</b>	TGF- $\beta$ can induce a G1 cell-cycle arrest	<b>37</b>
<b>1.12</b>	TGF- $\beta$ can trigger programmed cell death	<b>40</b>
<b>1.13</b>	The TGF- $\beta$ 1 signalling pathway and its alterations in human cancer	<b>42</b>
<b>1.14</b>	Schematic diagram of domain structure in representative IAP proteins	<b>46</b>
<b>1.15</b>	Ribbon diagrams of the survivin monomer and survivin dimer	<b>47</b>
<b>1.16</b>	Function of survivin in mitosis	<b>50</b>
<b>1.17</b>	Function of survivin as inhibitor of apoptosis	<b>52</b>
<b>2.1</b>	Calibration curve for serum AFP	<b>62</b>
<b>2.2</b>	Calibration curve for serum TGF- $\beta$ 1	<b>67</b>
<b>2.3</b>	Polymerization and probe annealing.	<b>78</b>
<b>2.4</b>	Strand displacement, cleavage and completion of polymerization	<b>79</b>
<b>2.5</b>	Amplification plots of TGF- $\beta$ 1 and GAPDH in different tissue samples	<b>85</b>
<b>3.1</b>	Box-plots of serum AFP level in HCV and HCC patients	<b>102</b>